Related Experiment Video
Updated: Aug 26, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Antineuropathic effects of the antibiotic derivative spicamycin KRN5500
David Borsook1, Annabel Davis Edwards
1Center for Functional Pain Neuroimaging and Therapy Research, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. dborsook@dtrx.com
Abstract:
Excellence in neuropathic pain management continues to challenge the ability of health care providers. Current medications are helpful but often create significant side effects or simply fail to provide adequate analgesia. We report here on a serendipitous finding of the successful attenuation of neuropathic pain in a patient with long-standing monoclonal gammopathy, Raynaud's disease, and neuropathic pain who received the trial chemotherapeutic agent KRN5500. This finding led to animal studies that have provided support for the possible use of KRN5500 in the treatment of neuropathic pain in humans as well as some insight into the possible mechanism(s) of action of this drug.
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Microbiota Modulation by Antibiotics
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Gram-positive Cell Wall Synthesis